BCMA chimeric antigen receptors and uses thereof

US11608382B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Aida Abujoub · Winchester, US
• John W. Blankenship · Acton, US
• Dexiu Bu · Melrose, US
• Tony Fleming · Stow, US
• Brian Holmberg · Somerville, US
• Connie Hong · Somerville, US
• Lu Huang · Riverdale, US
• Chonghui Zhang · Brookline, US

Key dates

• Filing date: Jun 12, 2019
• Grant date: Mar 21, 2023
• Expiry date: May 10, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.